# US 2016/0251352 A1 · Heterocyclic compound

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251352 A1
- Document ID: US20160251352A1
- Status: Published application
- Kind: A1
- Application number: 15/148,276
- Filed: 2016-05-06
- Published: 2016-09-01
- Earliest claimed: 2012-06-01
- Assignees: Takeda Pharmaceutical Company Limited
- Applicants: Takeda Pharmaceutical Company Limited
- Inventors: Hiroshi NARA; Masaki DAINI; Akira KAIEDA; Taku KAMEI; Toshihiro IMAEDA; Fumiaki KIKUCHI
- Web page: https://patentgrep.com/patent/US20160251352A1

## CPC

- C07D 471/04: Ortho-condensed systems
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides a compound having a superior JAK inhibitory action, which is useful as an agent for the prophylaxis or treatment of autoimmune diseases (rheumatoid arthritis, psoriasis, inflammatory bowel disease, Sjogren's syndrome, Behcet's disease, multiple sclerosis, systemic lupus erythematosus, etc.), cancer (leukemia, uterine leiomyosarcoma, prostate cancer, multiple myeloma, cachexia, myelofibrosis, etc.) and the like, or a salt thereof. The present invention relates to a compound represented by the formula wherein each symbol is as defined in the specification, or a salt thereof.

## Claims

### Claim 1

A compound represented by the formula (I):
wherein
Ring A moiety is a nitrogen-containing aromatic heterocycle
wherein
Q is a carbon atom or a nitrogen atom, and
X2 and X3 are each independently a carbon atom or a nitrogen atom, and any one of them is a nitrogen atom;
R1 is a hydrogen atom, a halogen atom, a cyano group, an acyl group, an optionally substituted C1-6 alkyl group, an optionally substituted C3-6 cycloalkyl group or an optionally substituted hydroxy group;
R2 is a substituted C1-2 alkyl group, an optionally substituted C3-6 alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, an optionally substituted carbocyclic group or an optionally substituted heterocyclic group; and
R3 is a substituted C1-2 alkyl group, an optionally substituted C3-6 alkyl group, an acyl group, an optionally substituted hydroxy group, an optionally substituted amino group, an optionally substituted carbocyclic group or an optionally substituted heterocyclic group,
provided that 3-(3-fluorophenyl)-1-trityl-1,5-dihydro-4H-pyrazolo[4,3-c]pyridin-4-one is excluded,
or a salt thereof.

### Claim 2 (depends on 1)

The compound or salt of claim 1, wherein
R1 is
(1) a hydrogen atom,
(2) a halogen atom,
(3) a cyano group,
(4) a carboxy group,
(5) a C1-6 alkyl-carbonyl group,
(6) a C1-6 alkoxy-carbonyl group,
(7) a carbamoyl group optionally mono- or di-substituted by C1-6 alkyl group(s),
(8) a C1-6 alkyl group optionally substituted by 1 to 3 hydroxy groups, or
(9) a C3-6 cycloalkyl group;
R2 is
(1) a C1-2 alkyl group substituted by 1 to 3 substituents selected from
(a) a C6-14 aryl group optionally substituted by 1 to 3 C1-6 alkoxy groups, and
(b) a 3- to 8-membered monocyclic non-aromatic heterocyclic group optionally substituted by 1 to 3 C1-6 alkyl groups,
(2) a C3-6 alkyl group optionally substituted by 1 to 3 substituents selected from
(a) a hydroxy group, and
(b) a C1-6 alkoxy group,
(3) a C3-10 cycloalkyl group optionally substituted by 1 to 3 substituents selected from
(a) a hydroxy group,
(b) a C1-6 alkyl group,
(c) an oxo group,
(d) a C1-6 alkylenedioxy group,
(e) a C6-14 aryl group,
(f) a halogen atom, and
(g) an amino group,
(4) a C6-14 aryl group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a C1-6 alkyl group optionally substituted by 1 to 3 halogen atoms,
(c) a cyano group,
(d) a carbamoyl group,
(e) an amino group, and
(f) a C1-6 alkoxy group,
(5) a 3- to 8-membered monocyclic non-aromatic heterocyclic group, or
(6) a 5- to 7-membered monocyclic aromatic heterocyclic group; and
R3 is
(1) a C1-2 alkyl group substituted by 1 to 3 substituents selected from a C6-14 aryl group optionally substituted by 1 to 3 sulfamoyl groups,
(2) a C3-10 cycloalkyl group,
(3) a C3-10 cycloalkenyl group,
(4) a C6-14 aryl group optionally substituted by 1 to 3 substituents selected from
(a) a halogen atom,
(b) a nitro group,
(c) a cyano group,
(d) a carbamoyl group optionally mono- or di-substituted by C1-6 alkyl group(s) optionally substituted by 1 to 3 substituents selected from
(i) a C1-6 alkoxy group,
(ii) a hydroxy group, and
(iii) an amino group optionally mono- or di-substituted by C1-6 alkyl group(s),
(e) a sulfamoyl group optionally mono- or di-substituted by C1-6 alkyl group(s),
(f) a C1-6 alkyl group optionally substituted by 1 to 3 substituents selected from
(i) a halogen atom,
(ii) a cyano group,
(iii) a hydroxy group,
(iv) a carbamoyl group optionally mono- or di-substituted by substituent(s) selected from a C1-6 alkyl group and a C3-10 cycloalkyl group,
(v) an amino group optionally mono- or di-substituted by C1-6 alkyl group(s), and
(vi) a 3- to 8-membered monocyclic non-aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from an oxo group and a halogen atom,
(g) a C1-6 alkoxy group optionally substituted by 1 to 3 substituents selected from
(i) a halogen atom,
(ii) a cyano group,
(iii) a hydroxy group, and
(iv) a carbamoyl group optionally mono- or di-substituted by substituent(s) selected from a C1-6 alkyl group optionally substituted by 1 to 3 C1-6 alkoxy groups,
(h) a C1-6 alkoxy-carbonyl group,
(i) an amino group optionally mono- or di-substituted by substituent(s) selected from
(i) a C1-6 alkyl-carbonyl group, and
(ii) a C1-6 alkyl group optionally substituted by 1 to 3 C1-6 alkoxy groups,
(j) a 3- to 8-membered monocyclic non-aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from
(i) an oxo group,
(ii) a C1-6 alkyl group,
(iii) a C1-6 alkyl-carbonyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group and a C1-6 alkoxy group,
(iv) a carbamoyl group optionally mono- or di-substituted by C1-6 alkyl group(s),
(v) a C1-6 alkylsulfonyl group, and
(vi) a halogen atom, and
(k) a C1-6 alkylenedioxy group,
(5) a 5- to 7-membered monocyclic aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from
(a) a carboxy group,
(b) a cyano group,
(c) a C1-6 alkoxy-carbonyl group,
(d) a carbamoyl group optionally mono- or di-substituted by substituent(s) selected from
(i) a C1-6 alkyl group optionally substituted by 1 to 3 substituents selected from a hydroxy group and a cyano group,
(ii) a C3-10 cycloalkyl group optionally substituted by 1 to 3 cyano groups,
(iii) a 5- to 7-membered monocyclic aromatic heterocyclic group optionally substituted by 1 to 3 C1-6 alkyl groups, and
(iv) a 3- to 8-membered monocyclic non-aromatic heterocyclic group,
(e) a 3- to 8-membered monocyclic non-aromatic heterocyclic group optionally substituted by 1 to 3 oxo groups,
(f) a C1-6 alkyl group optionally substituted by 1 to 3 substituents selected from
(i) a cyano group,
(ii) a carbamoyl group, and
(iii) a 3- to 8-membered monocyclic non-aromatic heterocyclic group optionally substituted by 1 to 3 oxo groups,
(g) a C3-10 cycloalkyl group,
(h) a 3- to 8-membered monocyclic non-aromatic heterocyclylcarbonyl group, and
(i) an amino group,
(6) a 8- to 12-membered fused aromatic heterocyclic group optionally substituted by 1 to 3 C1-6 alkyl groups,
(7) a 3- to 8-membered monocyclic non-aromatic heterocyclic group optionally substituted by 1 to 3 substituents selected from
(a) an oxo group, and
(b) a C1-6 alkyl group,
(8) a 8- to 12-membered fused non-aromatic heterocyclic group optionally substituted by 1 to 3 oxo groups, or
(9) an amino group optionally mono- or di-substituted by substituent(s) selected from
(a) a C6-14 aryl group optionally substituted by 1 to 3 substituents selected from
(i) a carbamoyl group, and
(ii) a sulfamoyl group,
(b) a C1-6 alkyl group optionally substituted by 1 to 3 substituents selected from a C6-14 aryl group optionally substituted by 1 to 3 C1-6 alkoxy groups, and
(c) a C6-14 aryl-carbonyl group.

### Claim 3 (depends on 1)

The compound or salt of claim 1, which is 4-(1-cyclopentyl-4-oxo-4,5-dihydro-1H-pyrrolo[3,2-c]pyridin-3-yl)thiophene-2-carboxamide.

### Claim 4 (depends on 1)

The compound or salt of claim 1, which is 2-(4-(1-(2,6-difluorophenyl)-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)phenyl)acetamide.

### Claim 5 (depends on 1)

The compound or salt of claim 1, which is 3-((1-cyclopentyl-4-oxo-4,5-dihydro-1H-pyrazolo[4,3-c]pyridin-3-yl)amino)benzenesulfonamide.

### Claim 6 (depends on 1)

A medicament comprising the compound or salt of claim 1.

### Claim 7 (depends on 6)

The medicament of claim 6, which is a janus kinase inhibitor.

### Claim 8 (depends on 6)

The medicament of claim 6, which is an agent for the prophylaxis or treatment of autoimmune disease.

### Claim 9 (depends on 1)

The compound or salt of claim 1 for use in the prophylaxis or treatment of autoimmune diseases.

### Claim 10 (depends on 1)

A method of inhibiting janus kinase in a mammal, which comprises administering an effective amount of the compound or salt of claim 1 to the mammal.

### Claim 11 (depends on 1)

A method for the prophylaxis or treatment of autoimmune diseases, which comprises administering an effective amount of the compound or salt of claim 1 to the mammal.

### Claim 12 (depends on 1)

Use of the compound or salt of claim 1 for the production of an agent for the prophylaxis or treatment of autoimmune diseases.
